Author: Yan Li; Jinyong Zhang; Ning Wang; Haibo Li; Yun Shi; Gang Guo; Kaiyun Liu; Hao Zeng; Quanming Zou
Title: Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput Screening Document date: 2020_1_29
ID: iu2ziccm_2
Snippet: The discovery and clinical application of specific drugs against 2019-nCoV is an effective means to alleviate the current epidemic. However, there are no clinically effective drugs for this virus for the moment. Although 2019-nCoV is significantly different from SARS-CoV, which breakout in Beijing 17 years before [3] , the sequence identity between themis as high as 79.5%. Further sequence alignment revealed that the similarity of the sequence of.....
Document: The discovery and clinical application of specific drugs against 2019-nCoV is an effective means to alleviate the current epidemic. However, there are no clinically effective drugs for this virus for the moment. Although 2019-nCoV is significantly different from SARS-CoV, which breakout in Beijing 17 years before [3] , the sequence identity between themis as high as 79.5%. Further sequence alignment revealed that the similarity of the sequence of the main protease between 2019-nCoV and SARS-CoV is up to 96.1%. Previous study demonstrated that the main protease of SARS-CoV is essential for the life cycle of the virus, and is considered to be an attractive target for drug development [4] . Thus, this protein could be used as a homologous target to screening drugs that inhibiting the replication and proliferation of 2019-nCoV.
Search related documents:
Co phrase search for related documents- attractive target and drug development attractive target: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- attractive target and drug screen: 1, 2, 3
- attractive target and life cycle: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
- attractive target and main protease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- attractive target and previous study: 1, 2, 3, 4
- attractive target and proliferation replication: 1, 2
- attractive target and SARS CoV main protease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60
- attractive target and sequence alignment: 1, 2
- attractive target and sequence identity: 1, 2
- attractive target and specific drug: 1, 2, 3, 4, 5
- attractive target and virus life cycle: 1, 2, 3, 4, 5, 6
- clinical application and current epidemic: 1, 2, 3
- clinical application and drug development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- clinical application and life cycle: 1, 2, 3
- clinical application and main protease: 1, 2, 3, 4, 5
- clinical application and previous study: 1
- clinical application and SARS CoV main protease: 1, 2, 3
- clinical application and sequence identity: 1, 2
- clinical application and specific drug: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date